[go: up one dir, main page]

IL125404A0 - 4-amino-pyrimidine derivatives medicaments containing these compounds their use and process for their production - Google Patents

4-amino-pyrimidine derivatives medicaments containing these compounds their use and process for their production

Info

Publication number
IL125404A0
IL125404A0 IL12540497A IL12540497A IL125404A0 IL 125404 A0 IL125404 A0 IL 125404A0 IL 12540497 A IL12540497 A IL 12540497A IL 12540497 A IL12540497 A IL 12540497A IL 125404 A0 IL125404 A0 IL 125404A0
Authority
IL
Israel
Prior art keywords
amino
compounds
production
pyrimidine derivatives
medicaments containing
Prior art date
Application number
IL12540497A
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996108631 external-priority patent/DE19608631A1/en
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of IL125404A0 publication Critical patent/IL125404A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL12540497A 1996-03-06 1997-03-03 4-amino-pyrimidine derivatives medicaments containing these compounds their use and process for their production IL125404A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1996108631 DE19608631A1 (en) 1996-03-06 1996-03-06 New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives
DE19629652A DE19629652A1 (en) 1996-03-06 1996-07-23 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation
PCT/EP1997/001057 WO1997032881A1 (en) 1996-03-06 1997-03-03 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production

Publications (1)

Publication Number Publication Date
IL125404A0 true IL125404A0 (en) 1999-03-12

Family

ID=26023531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12540497A IL125404A0 (en) 1996-03-06 1997-03-03 4-amino-pyrimidine derivatives medicaments containing these compounds their use and process for their production

Country Status (19)

Country Link
EP (1) EP0885226A1 (en)
JP (1) JP2000506847A (en)
KR (1) KR19990087550A (en)
CN (1) CN1212695A (en)
AU (1) AU710274B2 (en)
BG (1) BG102708A (en)
BR (1) BR9708312A (en)
CA (1) CA2243994A1 (en)
CZ (1) CZ281798A3 (en)
DE (1) DE19629652A1 (en)
EE (1) EE9800277A (en)
HU (1) HUP9901820A3 (en)
IL (1) IL125404A0 (en)
NO (1) NO984084D0 (en)
NZ (1) NZ331546A (en)
PL (1) PL328771A1 (en)
SK (1) SK120598A3 (en)
TR (1) TR199801749T2 (en)
WO (1) WO1997032881A1 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
EP1396489A1 (en) * 1999-01-27 2004-03-10 Pfizer Products Inc. Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
DK1676845T3 (en) 1999-11-05 2008-09-15 Astrazeneca Ab New quinazoline derivatives
WO2004113334A1 (en) 2003-06-24 2004-12-29 Neurosearch A/S Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2598489A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
US8530650B2 (en) * 2008-12-01 2013-09-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer
JP2012518657A (en) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー Combined anticancer treatment
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012520893A (en) 2009-03-18 2012-09-10 オーエスアイ・ファーマシューティカルズ，エルエルシー Combination cancer treatment comprising administration of an EGFR inhibitor and an IGF-1R inhibitor
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2751285B2 (en) 2011-08-31 2020-04-01 Genentech, Inc. Method for sensitivity testing of a tumour for a egfr kinase inhibitor
AU2012321248A1 (en) 2011-09-30 2014-04-24 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
CA2941010A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
CN107223163A (en) 2014-12-24 2017-09-29 豪夫迈·罗氏有限公司 Methods for treatment, diagnosis and prognosis of bladder cancer
PT3558955T (en) 2016-12-22 2021-10-19 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
CN111051306B (en) 2017-09-08 2023-01-03 美国安进公司 Inhibitors of KRAS G12C and methods of use thereof
MA52496A (en) 2018-05-04 2021-03-10 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
MX2020010836A (en) 2018-05-04 2021-01-08 Amgen Inc Kras g12c inhibitors and methods of using the same.
MA52564A (en) 2018-05-10 2021-03-17 Amgen Inc KRAS G12C INHIBITORS FOR CANCER TREATMENT
EP3802535B1 (en) 2018-06-01 2022-12-14 Amgen, Inc Kras g12c inhibitors and methods of using the same
EP3802537A1 (en) 2018-06-11 2021-04-14 Amgen Inc. Kras g12c inhibitors for treating cancer
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
AU2019384118A1 (en) 2018-11-19 2021-05-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
BR112021011989A2 (en) 2018-12-20 2021-09-08 Amgen Inc. KIF18A INHIBITORS
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
EP3897855B1 (en) 2018-12-20 2023-06-07 Amgen Inc. Kif18a inhibitors
JP2022513971A (en) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Heteroarylamide useful as a KIF18A inhibitor
CA3130080A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
MX2021014126A (en) 2019-05-21 2022-01-04 Amgen Inc FORMS IN SOLID STATE.
EP4007756A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Kif18a inhibitors
CN114391012A (en) 2019-08-02 2022-04-22 美国安进公司 Pyridine derivatives as KIF18A inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
CR20220240A (en) 2019-11-04 2022-08-03 Revolution Medicines Inc RAS INHIBITORS
PE20221278A1 (en) 2019-11-04 2022-09-05 Revolution Medicines Inc RAS INHIBITORS
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
EP4055017A1 (en) 2019-11-08 2022-09-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
EP4058453A1 (en) 2019-11-14 2022-09-21 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
JP2023505100A (en) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド Covalent RAS inhibitors and uses thereof
IL294484A (en) 2020-01-07 2022-09-01 Revolution Medicines Inc Dosage for shp2 inhibitor and methods for treating cancer
BR112022025550A2 (en) 2020-06-18 2023-03-07 Revolution Medicines Inc METHODS TO DELAY, PREVENT, AND TREAT ACQUIRED RESISTANCE TO RAS INHIBITORS
MX2023002248A (en) 2020-09-03 2023-05-16 Revolution Medicines Inc Use of sos1 inhibitors to treat malignancies with shp2 mutations.
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
MX2023012060A (en) 2021-04-13 2024-01-22 Nuvalent Inc Amino-substituted heterocycles for treating cancers with egfr mutations.
JP2024517845A (en) 2021-05-05 2024-04-23 レボリューション メディシンズ インコーポレイテッド RAS Inhibitors for Cancer Treatment
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
BR112023022819A2 (en) 2021-05-05 2024-01-16 Revolution Medicines Inc COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATES AND METHODS FOR TREATING CANCER IN A SUBJECT, FOR TREATING A DISORDER AND FOR INHIBITING A RAS PROTEIN IN A CELL
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
TW202340214A (en) 2021-12-17 2023-10-16 美商健臻公司 Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN119136806A (en) 2022-03-08 2024-12-13 锐新医药公司 Method for treating immune refractory lung cancer
IL317476A (en) 2022-06-10 2025-02-01 Revolution Medicines Inc Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE4431867A1 (en) * 1994-09-07 1996-03-14 Thomae Gmbh Dr K Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation

Also Published As

Publication number Publication date
CA2243994A1 (en) 1997-09-12
CN1212695A (en) 1999-03-31
EP0885226A1 (en) 1998-12-23
AU1925197A (en) 1997-09-22
NO984084L (en) 1998-09-04
DE19629652A1 (en) 1998-01-29
JP2000506847A (en) 2000-06-06
PL328771A1 (en) 1999-02-15
EE9800277A (en) 1999-02-15
KR19990087550A (en) 1999-12-27
TR199801749T2 (en) 1998-12-21
AU710274B2 (en) 1999-09-16
WO1997032881A1 (en) 1997-09-12
SK120598A3 (en) 1999-06-11
HUP9901820A2 (en) 1999-09-28
NZ331546A (en) 2000-03-27
CZ281798A3 (en) 1999-02-17
BR9708312A (en) 1999-08-03
BG102708A (en) 1999-09-30
HUP9901820A3 (en) 2001-10-29
NO984084D0 (en) 1998-09-04

Similar Documents

Publication Publication Date Title
IL125404A0 (en) 4-amino-pyrimidine derivatives medicaments containing these compounds their use and process for their production
AP9901556A0 (en) Sulpponamide derivatives process for their preparation and their use as medicaments
HUP0000068A3 (en) Process for producing ecteinascidin compounds, their use and pharmaceutical compositions containing them
HUP9901535A3 (en) Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9904521A3 (en) Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9802300A3 (en) N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP0001562A3 (en) Aminotriazole derivatives process for their preparation and medicaments containing the same
HUP9900625A3 (en) Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds
HUP9800138A3 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use
HU9602489D0 (en) New piperazine derivatives, process for producing them and pharmaceutical compositions containing them
HU906501D0 (en) Process for producing pyrimidine derivatives and pharmaceutical preparatives containing these compounds
AU4055895A (en) Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
HUP0002718A3 (en) Piperazine derivatives, process for their preparation and medicaments containing the same
HUP0000941A3 (en) Sulfamide derivatives, process for producing them, pharmaceutical compositions containing them and their use
HUP0001760A3 (en) Arylacyl pyridazine derivatives, pharmaceutical compositions containing them, process for producing them and use of the compounds for producing pharmaceutical compositions
HUP9600071A3 (en) Indolo-piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
HU911226D0 (en) Process for producing benzimidazolinon derivatives and pharmaceutical preparatives containing said compounds
HU9402832D0 (en) Imidazol-4-yl-piperidine derivatives, process for producing them and pharmaceutical use of them
HUT76065A (en) Indole derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9600876A3 (en) Benzonitril- and -fluoride derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9901739A3 (en) Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them
HUP0002952A3 (en) Benzimidazole derivatives, process for producing them, their use and pharmaceutical compositions containing them
HU9402187D0 (en) Heterocyclic compounds, process for producing them and pharmaceutical compositions containing them
HUP0104033A3 (en) 1-benzoyl-tetrahydropyridazine derivatives, process for their preparation, their use and medicaments containing the compounds
GB9617893D0 (en) New pharmaceutical derivatives, process for obtaining them and pharmaceutical compositions containing them